Axon Enterprise (NASDAQ:AXON) Price Target Raised to $800.00

Axon Enterprise (NASDAQ:AXON) had its target price upped by Robert W. Baird from $600.00 to $800.00 in a report issued on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on AXON. Needham & Company LLC lifted their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Northland Securities lifted their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, JMP Securities lifted their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $488.67.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $687.69 on Friday. The company’s fifty day moving average price is $516.24 and its 200 day moving average price is $393.77. Axon Enterprise has a 1 year low of $232.78 and a 1 year high of $698.67. The stock has a market capitalization of $52.44 billion, a P/E ratio of 177.70, a P/E/G ratio of 15.13 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 25,811 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the sale, the president now directly owns 228,166 shares in the company, valued at approximately $82,103,253.44. The trade was a 10.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Julie A. Cullivan sold 1,261 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the completion of the sale, the director now owns 2,392 shares in the company, valued at approximately $1,631,487.52. This trade represents a 34.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 129,739 shares of company stock worth $60,108,622 in the last quarter. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

Institutional investors and hedge funds have recently bought and sold shares of the stock. Groupama Asset Managment purchased a new stake in Axon Enterprise during the third quarter worth about $200,000. Massachusetts Financial Services Co. MA purchased a new stake in Axon Enterprise during the third quarter worth about $120,553,000. International Assets Investment Management LLC purchased a new stake in Axon Enterprise during the third quarter worth about $871,860,000. Westfield Capital Management Co. LP increased its stake in Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares during the period. Finally, 1832 Asset Management L.P. increased its stake in Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after purchasing an additional 114,800 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.